Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 tags : Approval save search
Photon Control Securityholders Approve Acquisition by MKS Instruments
Published: 2021-06-29 (Crawled : 21:00) - globenewswire.com
MKSI | $110.73 -1.21% 85K
|
Electronic Technology
|
| O: -0.19%
H: 0.26%
C: -0.02%
security acquisition approval
Approval of CN-KCS Voting Trust Is Essential Next Step for Shippers and Others to Have Their Say on What Constitutes Enhanced Competition
Published: 2021-06-29 (Crawled : 17:00) - globenewswire.com
CNI | News | $127.47 0.24% 270K
|
Transportation
|
| O: 0.05%
H: 0.83%
C: 0.66%
approval
Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib)
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.03%
H: 0.0%
C: -5.27%
fda biopharma fda approval approval lonafarnib rare
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License ApplicationCompany Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
VCEL | $43.38 -1.09% 70K
|
Health Technology
|
| O: -15.34%
H: 4.46%
C: 0.63%
MDWD | $16.655 -1.97% 8.5K
|
Health Technology
|
| O: -33.51%
H: 14.13%
C: 8.53%
fda potential therapy license approval
FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
ABMD | $381.02 0.06% 0.07%
|
Health Technology
|
| O: -0.36%
H: 1.48%
C: 0.63%
fda heart approval granted grant
Regulatory Approval Remains a Major Challenge for Cell-Based Meat Despite $800 Million in Funding
Published: 2021-06-29 (Crawled : 12:15) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -0.31%
H: 0.56%
C: -0.19%
funding approval
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.